Derek Brown
VP Marketing
Claimed by owner Chiasma
Former names:
Oral Therapeutic Options for Patients with Rare Diseases
Acquired by Amryt Pharma Group on Aug, 2021
Chiasma
www.globenewswire.com
•
Aug 5, 2021
Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
www.thepharmaletter.com
•
Mar 23, 2021
Positive Phase III data for Mycapssa
www.biospace.com
•
Sep 18, 2020
Chiasma's Octreotide Capsules Could Be Answer to Acromegaly Treatment Burdens BioSpace
en.globes.co.il
•
Jun 29, 2020
Chiasma wins FDA approval for acromegaly treatment
www.globenewswire.com
•
Apr 22, 2020
Chiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
www.globenewswire.com
•
Apr 8, 2020
Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners
www.globenewswire.com
•
Jan 13, 2020
Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission
en.globes.co.il
•
Jul 23, 2019
Chiasma Phase III acromegaly trial meets all endpoints
en.globes.co.il
•
Apr 8, 2019
Drug developer Chiasma raises $34.5 million on Nasdaq
www.globes.co.il
•
Jun 15, 2016
Israeli drug developer Chiasma fires 33% of work force
www.globes.co.il
•
Jul 19, 2015
Chiasma raises $102m in Nasdaq IPO
www.globes.co.il
•
Jul 8, 2015
Biopharma co Chiasma updates Nasdaq IPO terms
news.nocamels.com
•
Jun 17, 2015
Chiasma To Raise $86M In IPO
en.globes.co.il
•
Mar 1, 2015
Drug development co Chiasma raises $70m
www.globes.co.il
•
Dec 30, 2014
Drug development co Chiasma raises $33.5m
www.globes.co.il
•
Aug 6, 2014
Roche cancels $600m Chiasma deal
www.biospace.com
•
Nov 5, 2006
Chiasma Raises $44 Million Series C To Fund Clinical Testing, Advance Technology BioSpace
About
Chiasma is a clinical late-stage biopharmaceutical company focused on improving the lives of patients with rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop and ultimately commercialize oral medications that are currently available only as injections.
Chiasma is evaluating proteins, peptides, and small molecule drugs that are currently available only by injection but which could potentially be converted to oral delivery using the companys TPE technology.
In June 2020, the company received FDA approval for its MYCAPSSA (octreotide) capsules for long-term maintenance treatment in patients with acromegaly. MYCAPPSA is a treatment for chronic acromegaly that can be taken orally in pill form rather than by injection.
Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary.
In August 2021, Chiasma was acquired by Amryt , a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
Chiasma is evaluating proteins, peptides, and small molecule drugs that are currently available only by injection but which could potentially be converted to oral delivery using the companys TPE technology.
In June 2020, the company received FDA approval for its MYCAPSSA (octreotide) capsules for long-term maintenance treatment in patients with acromegaly. MYCAPPSA is a treatment for chronic acromegaly that can be taken orally in pill form rather than by injection.
Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary.
In August 2021, Chiasma was acquired by Amryt , a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
MYCAPSSA
Geographic markets
United States
News
(17)
www.globenewswire.com
•
Aug 5, 2021
Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
www.thepharmaletter.com
•
Mar 23, 2021
Positive Phase III data for Mycapssa
www.biospace.com
•
Sep 18, 2020
Chiasma's Octreotide Capsules Could Be Answer to Acromegaly Treatment Burdens BioSpace
en.globes.co.il
•
Jun 29, 2020
Chiasma wins FDA approval for acromegaly treatment
www.globenewswire.com
•
Apr 22, 2020
Chiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
www.globenewswire.com
•
Apr 8, 2020
Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners
www.globenewswire.com
•
Jan 13, 2020
Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission
en.globes.co.il
•
Jul 23, 2019
Chiasma Phase III acromegaly trial meets all endpoints
en.globes.co.il
•
Apr 8, 2019
Drug developer Chiasma raises $34.5 million on Nasdaq
www.globes.co.il
•
Jun 15, 2016
Israeli drug developer Chiasma fires 33% of work force
www.globes.co.il
•
Jul 19, 2015
Chiasma raises $102m in Nasdaq IPO
www.globes.co.il
•
Jul 8, 2015
Biopharma co Chiasma updates Nasdaq IPO terms
news.nocamels.com
•
Jun 17, 2015
Chiasma To Raise $86M In IPO
en.globes.co.il
•
Mar 1, 2015
Drug development co Chiasma raises $70m
www.globes.co.il
•
Dec 30, 2014
Drug development co Chiasma raises $33.5m
www.globes.co.il
•
Aug 6, 2014
Roche cancels $600m Chiasma deal
www.biospace.com
•
Nov 5, 2006
Chiasma Raises $44 Million Series C To Fund Clinical Testing, Advance Technology BioSpace
The Team
(3)
DB
SK
Shoshie Katz
VP RA/QA
GP
Gary Patou
Head of Clinical
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
$102M
Jul 2015
Stock Exchange
NASDAQ
Valuation
$562M
$102M
Delisting
Aug 2021
Stock Exchange
NASDAQ
Due to acquisition
M&A
Undisclosed
Aug 2021
Type
Acquisition
Was acquired by
Amryt Pharma Group
Undisclosed
Private Equity Funding
Seed
$2M
Mar 2003
1 Investors
$2M
B Round
$7.7M
Sep 2005
4 Investors
$7.7M
C Round
$44M
Nov 2006
4 Investors
$44M
Debt Financing
$2.8M
Nov 2009
$2.8M
Debt Financing
$10M
Jun 2011
$10M
Debt Financing
$3M
Jun 2012
$3M
D Round
$33.5M
Dec 2014
4 Investors
$33.5M
E Round
$70M
Feb 2015
7 Investors
$70M
Post-IPO Equity Funding
$34.5M
Apr 2019
$34.5M
Others
Academic Techonology
Apr 2001
undefined
Oral Delivery of Molecules and Poorly Absorbed Drugs
Media gallery
(0)Locations
Israel
Golda Meir Street 5, Ness Ziyyona, Israel
Offices Abroad
140 Kendrick Street, Needham, MA, USA
Locations
Israel
Golda Meir Street 5, Ness Ziyyona, Israel
Offices Abroad
140 Kendrick Street, Needham, MA, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,